PMGC unit NorthStrive Biosciences posts positive Phase III results in AI drug discovery program with Yuva Biosciences

PMGC Holdings Inc.

PMGC Holdings Inc.

ELAB

0.00
  • PMGC affiliate NorthStrive Biosciences reported positive Phase III results from its AI drug-discovery program with Yuva Biosciences.
  • Yuva’s MitoNova AI platform identified four small-molecule candidates that significantly increased ANT1 protein expression in primary human skeletal muscle cells.
  • Top performers showed dose-dependent ANT1 induction, led by C2 up to +50%, C4 up to +48%, C1 up to +46%.
  • NorthStrive is evaluating confirmatory testing in a more mature skeletal muscle model to support further development for muscle-preservation applications.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-073986), on July 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.